We specialize in developing targeted therapies using advanced inhalation technologies delivering treatments directly to the site of disease with the aim of treating complex medical challenges. Our research focuses on respiratory diseases and transplant medicine, with a strong commitment to understanding disease mechanisms and creating innovative treatments. Through collaboration with leading researchers and institutions, we translate cutting-edge discoveries into transformative therapies
KX01 is an inhaled anti-inflammatory treatment for lung transplant patients with Bronchiolitis Obliterans Syndrome (BOS). No treatments for BOS are approved by FDA or EMA.
In pre-clinical studies KX01 have showed to address the main pathology in BOS – i.e. inflammation, fibrosis and vasculopathy.